GlassScriptPhysician profile
Rakesh Kilari
NPI 1750536736
$2,190.47
in general payments reported to CMS, 2019-2025
24 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $822 · 2020: $604 · 2021: $78.19 · 2022: $131 · 2023: $83.84 · 2024: $179 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554 · Education: $2.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.90 |
| Education | $2.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $496.15 | 2019-2025 | Nxstage System One, Velphoro |
| Astrazeneca Pharmaceuticals LP | $305.64 | 2019-2025 | Farxiga |
| Vifor Pharma, INC. | $248.18 | 2019-2023 | Veltassa |
| Amgen INC. | $184.19 | 2019-2025 | Tavneos, Krystexxa |
| Mallinckrodt Hospital Products INC. | $120.75 | 2020 | |
| Akebia Therapeutics INC | $120.52 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $100.81 | 2021-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $96.32 | 2019-2025 | Jynarque |
| Nxstage Medical, INC. | $74.32 | 2022 | |
| Horizon Therapeutics Plc | $63.58 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.33 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $52.66 | 2019-2020 | |
| Genentech USA, INC. | $30.29 | 2019-2020 | |
| Ardelyx, INC. | $29.18 | 2025 | Ibsrela |
| Novo Nordisk INC | $28.53 | 2025 | Rybelsus, Ozempic |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $28.08 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $26.26 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.83 | 2024 | |
| Glaxosmithkline, LLC. | $23.44 | 2023 | Benlysta |
| Genzyme Corporation | $22.64 | 2019 | |
| Shire North American Group INC | $20.30 | 2019 | |
| Lilly USA, LLC | $18.97 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $15.18 | 2019 | |
| Travere Therapeutics, INC. | $2.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Kilari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.